TRIAL DETAIL
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 07/01/2011 |
Age of Trial (yrs) 13.4 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
PI3K inhibitor + MEK inhibitor |
|||
Strategy: |
Block related tumor signal paths |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
12876, 2010-024082-45 |
|||
Sponsor: |
Bayer |
|||
Patient Contact: |
For trial location information (Phone Menu Options '3' or '4'
(+)1-888-84 22937 |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Intravenous |
|||
Trial Notes: |
Copanlisib + Refametinib |
|||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
9023 E. Desert Cove Ave. |
Scottsdale |
AZ |
85260 |
USA |
|
1505 Holcombe Blvd. |
Houston |
TX |
77030 |
USA |
|
Breisacher Straße 117 |
Freiburg |
D-79106 |
Germany |
||
Rotterdam |
Netherlands |